Indomethacin analogs for the treatment of castrate-resistant prostate cancer
Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.
1. A method for inhibiting undesirable aldo-keto reductase family 1, member C3 (AKR1C3) biological activity in a subject, the method comprising:
(a) providing a subject with a tumor associated with undesirable AKR1C3 biological activity; and
(b) administering to the subject an effective amount of a compound of Formula II:
wherein:
R1 is selected from the group consisting of OH, OCH 3 , OCH 2 CH 3 and HNSO 2 X;
R2 is hydrogen or R—or S—C 1 -C 6 alkyl;
R3 is hydrogen or R—or S—C 1 -C 6 alkyl;
R4 is C 1 to C 6 alkyl;
R5 is hydrogen, C 1 to C 6 alkoxy or halogen;
R10 is present in two, three, four, or five positions in the phenyl ring and each instance is independently selected from the group consisting of hydrogen, halogen, nitro, C 1 to C 6 alkyl, singly or multiply halogen substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, amino, and hydroxy;
X is methyl or singly or multiply halogen substituted methyl; phenyl, optionally singly or multiply substituted phenyl or thiophenyl, wherein the single or multiple substitutions of the phenyl or thiophenyl are each independently selected from the group consisting of halogen, nitro, C 1 to C 6 alkyl, singly or multiply halogen substituted C 1 to C 6 alkyl, trifluoromethyl, acetyl, isopropyl, C 1 to C 6 alkoxy, trifluoromethyloxy, phenoxy, cyano, hydroxy, and amino;
m is 0 or 1,
or a pharmaceutically acceptable salt thereof,
and further wherein the effective amount is effective to decrease the biological activity of the AKR1C3 polypeptide in the tumor sufficiently to produce a measurable amelioration of a symptom associated with the undesirable AKR1C3 biological activity in the subject.
2. A method for treating a prostate tumor in a subject, the method comprising:
(a) providing a subject having a prostate tumor, wherein the prostate tumor results from undesirable expression of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide; and
(b) administering to the subject a therapeutically effective amount of a compound having one of the following structures:
wherein:
R1 is selected from the group consisting of OH, OCH 3 , OCH 2 CH 3 and HNSO 2 X;
R2 is hydrogen or R—or S—C 1 -C 6 alkyl;
R3 is hydrogen or R—or S—C 1 -C 6 alkyl;
R4 is C 1 to C 6 alkyl;
R5 is hydrogen, C 1 to C 6 alkoxy or halogen;
R10 is present in two, three, four, or five positions in the phenyl ring and each instance is independently selected from the group consisting of hydrogen, halogen, nitro, C 1 to C 6 alkyl, singly or multiply halogen substituted C 1 to C 6 alkyl, C 1 to C 6 alkoxy, amino, and hydroxy;
X is methyl or singly or multiply halogen substituted methyl; phenyl, optionally singly or multiply substituted phenyl or thiophenyl, wherein the single or multiple substitutions of the phenyl or thiophenyl are each independently selected from the group consisting of halogen, nitro, C 1 to C 6 alkyl, singly or multiply halogen substituted C 1 to C 6 alkyl, trifluoromethyl, acetyl, isopropyl, C 1 to C 6 alkoxy, trifluoromethyloxy, phenoxy, cyano, hydroxy, and amino;
m is 0 or 1,
or a pharmaceutically acceptable salt thereof,
and further wherein the therapeutically effective amount is effective to decrease a biological activity of the AKR1C3 polypeptide sufficiently to produce a measurable response in the subject.
3. The method of claim 1 , wherein the compound has one of the following structures:
4. The method of claim 1 , wherein the subject is a mammal.
5. The method of claim 1 , wherein the tumor is a prostate tumor.
6. The method of claim 5 , wherein the prostate tumor is a castrate-resistant prostate tumor.
7. The method of claim 2 , wherein the compound has one of the following structures:
8. The method of claim 2 , wherein the prostate tumor is a castrate-resistant prostate tumor.
9. The method of claim 2 , wherein the administering is via a route selected from the group consisting of peroral, intravenous, intraperitoneal, inhalation, intraprostatic, and intratumoral.
10. The method of claim 2 , wherein the measurable response in the subject comprises an inhibition of growth of cells of the prostate tumor.